vimizim
biomarin international limited - recombinant human n-acetylgalactosamine-6-sulfatase - mukopolisacharydoza iv - inne przewodu pokarmowego i przemianę materii narzędzia, - vimizim jest wskazany w leczeniu mukopolisacharydozy typu iva (zespół morquio a, mps iva) u pacjentów w każdym wieku.
dupixent
sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - Środki do zapalenia skóry, z wyłączeniem kortykosteroidy - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
sortis 20 20 mg tabletki powlekane
upjohn eesv - atorvastatinum calcicum - tabletki powlekane - 20 mg
stamaril nie mniej niż 1000 j.m. żywego atenuowanego wirusa żółtej febry, szczep 17 d-204/0,5 ml; szczepionka 1-dawkowa proszek i rozpuszczalnik do sporządzania zawiesiny do wstrzykiwań
sanofi pasteur - żywy atenuowany wirus żółtej febry szczep 17 d-204 - proszek i rozpuszczalnik do sporządzania zawiesiny do wstrzykiwań - nie mniej niż 1000 j.m. żywego atenuowanego wirusa żółtej febry, szczep 17 d-204/0,5 ml; szczepionka 1-dawkowa
sortis 40 40 mg tabletki powlekane
upjohn eesv - atorvastatinum calcicum trihydricum - tabletki powlekane - 40 mg
sortis 10 10 mg tabletki powlekane
upjohn eesv - atorvastatinum calcicum trihydricum - tabletki powlekane - 10 mg
zofran 4 mg/5 ml syrop
novartis poland sp. z o.o. - ondansetroni hydrochloridum dihydricum - syrop - 4 mg/5 ml
efectin er 75 75 mg kapsułki o przedłużonym uwalnianiu
upjohn eesv - venlafaxini hydrochloridum - kapsułki o przedłużonym uwalnianiu - 75 mg
efectin er 150 150 mg kapsułki o przedłużonym uwalnianiu
upjohn eesv - venlafaxini hydrochloridum - kapsułki o przedłużonym uwalnianiu - 150 mg
zofran zydis 4 mg liofilizat doustny
novartis poland sp. z o.o. - ondansetronum - liofilizat doustny - 4 mg